AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
Abilify launched in Europe.
2004 JUL 24 - (NewsRx.com & NewsRx.net) -- Bristol-Myers Squibb Company (BMY) and Otsuka Pharmaceutical Co., Ltd., announced the European launch of Abilify (aripiprazole), the first in a new generation of antipsychotic medications, at the 24th Annual Meeting of the Collegium Internationale Neuro-Psychopharmacologicum (CINP), a key psychiatry conference held in Paris, France.
Two in every three patients rated Abilify as "much better, I prefer this medication" 8 weeks after switching from a previous antipsychotic treatment, according to results of BETA (Broad Effectiveness Trial with Aripiprazole), a naturalistic study involving 1500 patients, presented at the congress.
"Abilify offers an effective new option for millions of people affected by schizophrenia in Europe," said professor Rajiv Tandon, professor of psychiatry at the University of Michigan Medical Centre, Ann Arbor, Michigan. "Preference of medication is a key factor in helping patients to stay on therapy and avoid relapse," he continued.
BETA was conducted in a "real world" setting, where physicians prescribed Abilify or another antipsychotic (in a four to one ratio) to patients who needed to switch treatment because of lack of effect or intolerable side effects.
The results of BETA showed that two out of three patients and more than half of their caregivers rated Abilify as 'much better, I prefer this medication' 8 weeks after switching from a previous antipsychotic treatment. Abilify showed a beneficial effect after 1 week of treatment, and by the end of the 8-week study, 69% of patients taking Abilify were rated by physicians as 'much improved' or 'very much improved'.
Abilify delivers short and long-term efficacy, controls the symptoms of schizophrenia, and is enhanced by a comprehensive safety and tolerability profile. Abilify is the first dopamine system stabilizer used to treat schizophrenia and it is suggested that it works in a different way to all other antipsychotics.
Due to its unique mechanism of action, Abilify works by decreasing dopamine activity where D2 receptors are over stimulated and increasing dopamine activity where they are under stimulated, thus creating dopamine stabilization in certain areas of the brain.
- U.S. Food and Drug Administration Approves ABILIFY(R) (aripiprazole) for...
- Press release article from: PR Newswire November 6, 2007 700+ words
...Safety and Tolerability of ABILIFY in Pediatric Patients Ages 13-17 with Schizophrenia...innovative therapies, such as ABILIFY, to help patients, including adolescents...efficacy and safety of ABILIFY in pediatric patients, 13-17 years old...
- New Data and Analyses Demonstrate ABILIFY(R) (Aripiprazole) Effective at...
- Press release article from: PR Newswire May 5, 2004 700+ words
...these data show that patients taking ABILIFY experience some side effects...Significantly more patients responded with ABILIFY as compared to placebo...with bipolar I disorder, patients receiving ABILIFY showed significantly prolonged...
- ABILIFY approved for adolescent patients with schizophrenia.(Industry News)
- Magazine article from: Pharmaceutical Processing December 1, 2007 700+ words
...The FDA first approved ABILIFY for the treatment of...options for adolescent patients with schizophrenia were...this new indication for ABILIFY provides an additional...treatment option for these patients." This approval is...significant improvement with ABILIFY compared to placebo...
- FDA clears Abilify in pediatric bipolar patients.
- Newspaper article from: Pharma Marketletter March 10, 2008 700+ words
...supplemental New Drug Application for Abilify (aripiprazole) for the acute treatment...without psychotic features in pediatric patients aged10 to 17. The drug has been...Disorder that demonstrated efficacy with Abilify compared to placebo on the primary...
- Clinical Study Shows Intramuscular Administration of Aripiprazole (Abilify(R))...
- Press release article from: PR Newswire May 5, 2004 700+ words
...treated with ABILIFY. Patients should be appropriately...antipsychotic drugs, ABILIFY should be used cautiously if the patient has a history of seizures. Patients should not drive or...until they are certain ABILIFY does not affect them...
- Abilify Has Made Strong Gains in Patient Share Across All Lines of Therapy...
- Press release article from: PR Newswire July 23, 2009 700+ words
...When Treating Patients, According...Decision Resources Patient-Flow Forecasts...finds that the patient share of Bristol...Otsuka's Abilify has grown in...schizophrenia patients. Abilify is second to...first-line patient share grew...
- Otsuka America Pharmaceutical, Inc. Receives Frost & Sullivan's 2004 Product...
- Press release article from: PR Newswire September 15, 2004 700+ words
...from date of launch, Abilify is one of the most successful...receive this award for Abilify," said Hiromi Yoshikawa...may be attributed to Abilify's proven efficacy and...1%). For offering patients and their healthcare...dedicated to improving patient's health and the quality...
- ABILIFY(R) (aripiprazole) Supplemental New Drug Application for Pediatric...
- Press release article from: PR Newswire June 5, 2007 700+ words
...for at least 6 weeks* ABILIFY Injection is indicated...Physicians who elect to use ABILIFY for extended periods...drug for the individual patient. IMPORTANT SAFETY INFORMATION: Elderly patients with dementia-related...respectively). ABILIFY is not approved for the...